To the editor:
Vascular complications after splenectomy for hematologic disorders
In a recent issue of Blood, Crary and Buchanan published the most perceptive and comprehensive review to date of thrombotic vascular complications arising with functional or surgical asplenia in patients with hematologic, and especially hemolytic, disorders. 1 Their overview of the literature presents a great deal of food for thought regarding the apparent role of splenic function in protecting against thromboembolic disease, including venous thrombosis, pulmonary thromboembolism, and even arteriosclerosis and pulmonary hypertension. As the authors describe, these risks are reported even in subjects without hematologic disease who undergo splenectomy, but chronic hemolytic disease may compound this risk. I would like to point out 2 important additional pathophysiologic links.
The authors discuss the paradox that the incidence of arteriosclerotic events is lower in hereditary spherocytosis patients with intact spleens compared with their hematologically unaffected first degree relatives, and this low risk of arteriosclerosis is shared with patients with sickle cell disease. Crary and Buchanan propose a protective effect of hemolysis, mediated possibly by the lower serum cholesterol level seen in several forms of anemia. 2 Importantly, clearance of hemoglobinhaptoglobin or heme-hemopexin complexes by CD163-and CD91expressing reticuloendothelial macrophages triggers induction of hemeoxygenase-1 (HO-1), an enzyme that performs the first committed step in heme catabolism. 3 Besides producing carbon monoxide, a molecule with putative antiapoptotic, anti-inflammatory, and antiproliferative properties, HO-1 itself has similar protective functions, as do its metabolic products, biliverdin and bilirubin. I would suggest that part of the paradoxical protective benefit of hemolytic anemia against coronary arteriosclerosis in patients in part involves this induction of HO-1 and production of carbon monoxide, biliverdin, and bilirubin. Supporting this idea, HO-1 gene transfer experiments in mice protect against the development of arteriosclerosis. 4 In patients with chronic hemolysis, I agree with Crary and Buchanan that loss of splenic function shifts the predominant site of hemolysis from extravascular to intravascular. More specifically, Westerman and colleagues have observed that plasma hemoglobin and microparticle levels are higher in splenectomized thalassemia patients than those with intact splenic function. 5 Although in a nonrandomized study such as this, splenectomy might simply be a marker of patients who underwent splenectomy due to more severe disease, the findings are fully consistent with a delay in hemolysis, but with a proposed shift of site of hemolysis to intravascular, causing plasma hemoglobin levels to rise. The significance of this shift lies in the pathologic effect of plasma hemoglobin, which is documented to scavenge nitric oxide. This decreased nitric oxide bioavailability promotes a generalized vasculopathy phenotype of vasoconstriction, smooth muscle proliferation, and activation of adhesiveness of platelets and endothelial cells, with particular affinity to the pulmonary vasculature. 6 Furthermore, microparticles are believed to be prothrombotic. 7 I would like to commend Drs Crary and Buchanan for their valuable contribution to the literature on vascular disease and splenic function. Blood readers should also be aware of the emerging biology of heme-induced HO-1 vasculoprotection and of splenectomy-associated shifts of hemolysis promoting a state of relative nitric oxide deficiency. It is likely that these proposed mechanisms are only part of a multifactorial pathobiology linking asplenia and vasculopathy. To the editor:
Restoration of the human stem cell niche after stem cell transplantation
Recently, Dominici et al very elegantly demonstrated restoration of the osteoblastic hematopoietic stem cell (HSC) niche after lethal marrow radioablation in mice. 1 Based on their data, the authors propose a model in which radiation induced an increase in stromal cell-derived factor 1␣ (SDF-1␣), causing the attraction of CXCR4positive megakaryocytes that survived radiation. A concomitant increase in platelet-derived growth factor-␤ (PDGF-␤) and basic fibroblast growth factor (bFGF) levels, known to promote osteoblast proliferation, leads to restoration of the HSC niche as demonstrated by local engraftment of transplanted HSCs. The effect of radiation on bone marrow (BM) SDF-1␣ levels in human subjects is unknown. Moreover, data on SDF-1␣ levels following nonmyeloablative regimens, which are increasingly used in clinical practice, are lacking. We determined SDF-1␣ levels in BM and peripheral blood (PB) of 5 patients who underwent an allogeneic stem cell transplantation. Samples were taken on the first day of the conditioning regimen and on the day of the stem cell infusion ( Figure 1A ). Indeed, we were able to show a significant 2.8-fold increase (Ϯ 1.8 SD, P ϭ .04, Figure 1B) in BM SDF-1␣ levels in patients with hematologic malignancies, being treated with nonmyeloablative or myeloablative conditioning regimens. A similar although less pronounced increase in PB SDF-1␣ levels was observed (1.7 Ϯ 1.1, Figure 1B) . In agreement with the findings of Dominici et al in animals, the increase in protein levels was found to be the result of induction of SDF-1␣ gene expression, as BM SDF-1␣ mRNA copies increased a mean of approximately 40-fold, correlating with the increase in SDF-1 BM protein levels (r ϭ 0.92; P ϭ .03).
Interestingly, there were indications that the increase in SDF-1␣ was dependent on the type of conditioning regimen. In the sole patient being mildly conditioned with fludarabine/lowdose total body irradiation (TBI) no increase in bone marrow SDF-1␣ mRNA was found, corresponding with only a minor increase in BM SDF-1 protein levels (from 6.0 to 7.5 ng/mL, see outlier at Tx, Figure 1B ). In this single patient, platelets did not recover more than 100 ϫ 10 9 /L in 100 days. In contrast, the other 4 patients, showing a more pronounced increase in BM SDF-1␣ mRNA (2.0-to 104.0-fold increase) and protein levels (1.4-to 5.2-fold increase), recovered completely within 20 days. This observation supports the hypothesis of Dominici et al that bone marrow SDF-1␣ levels improve stem cell engraftment. To substantiate the observation that conditioning with fludarabine/low dose TBI has only limited effects, we studied PB SDF-1␣ levels in an Effect of myeloablative and nonmyeloablative regimens on SDF-1 protein levels in peripheral blood and bone marrow. SDF-1 levels (in ng/mL) were determined in both PB plasma and BM plasma before the conditioning regimen (before CR) and at the day of stem cell transplantation (at Tx). *P ϭ .043 BM before conditioning regimen vs PB before conditioning regimen. #P ϭ .043 BM at Tx vs BM before conditioning regimen. ∧P ϭ .043 BM at Tx vs PB at Tx. F indicates outlier (before CR; conditioned with myeloablative cyclophosphamide/TBI, at Tx; conditioned with mild nonmyeloablative fludarabine/low-dose TBI). Gray boxes indicate interquartile range (between 75th and 25th percentiles). Horizontal black line through box indicates median. Error bars indicate range.
